Navigation Links
Cell Therapeutics, Inc. Announces $6.5 Million Offering
Date:11/30/2007

SEATTLE, Nov. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has entered into agreements to sell approximately $6.5 million of its 7% Convertible Preferred Stock and warrants in a registered offering to several institutional investors, including certain of its existing securities holders. CTI will sell Series D convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of Series D convertible preferred stock. The Preferred Stock will be convertible into shares of common stock beginning on or about December 3, 2007, at a conversion price of $2.6125 per share. Purchasers will also receive warrants to purchase common stock in an amount equal to 50% of their total investment amount divided by $2.6125, which warrants will have an exercise price of $2.55 per share, which is equal to the closing bid price of the Company's common stock as reported on the NASDAQ Global Market on November 29, 2007. The warrants will not be exercisable until six months following the closing. The Company intends to use the proceeds of the offering towards the closing of its purchase of ZEVALIN(R) from Biogen Idec Inc. and for general corporate purposes.

The offering is expected to close on December 3, 2007, subject to certain closing conditions.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the preferred stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our Convertible Preferred Stock or warrants. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Miami Periodontist ... 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry held ... its annual Global Symposium at the Fontainebleau Hotel located in Miami Beach, FL. ...
(Date:4/24/2017)... Greensboro, NC and Seattle, WA (PRWEB) , ... ... ... currently utilized by 75+ leading lifestyle brands, work wear distributors and International relief ... diseases they can carry. The company also offers lifestyle and work wear collections ...
(Date:4/24/2017)... ... April 24, 2017 , ... A 2-in-1 ... the same place. From 101 Water Texas, here are the ways in which ... enjoy a continuous supply of pure, fresh, oxygenated water, with both cold and ...
(Date:4/23/2017)... , ... April 23, 2017 , ... ... managed services announced the achievement of Cisco Select certification and SMB specialization. ... United States. , In earning the Select Certification, Altura fulfilled the ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of the Year, ... providing information destruction , recycling, and compliance services to businesses throughout ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
Breaking Medicine Technology: